Gregory Davis, Ph.D., serves as Sangamo’s head of technology. He leads the teams responsible for the discovery and optimization of novel zinc finger proteins (ZFPs), enabling their translation into genomic medicines. He joined Sangamo Therapeutics in 2020 as Vice President of Genome Engineering. Dr. Davis has spent over 20 years in academia and biotech, working in the areas of genome editing, cell engineering, and directed protein evolution.

Prior to joining Sangamo, Dr. Davis served as the head of genome engineering at Sigma-Aldrich, where his team collaborated with Alan Lambowitz (Univ. Of Texas, Austin) to develop and commercialize the first RNA-guided systems for bacterial genome editing based on group II introns. In 2007, he and his team began working in partnership with Sangamo to develop ZFN synthesis processes to launch the world’s first genome editing tools for human somatic cell research in academia, biotech and pharma. They subsequently spearheaded a widely adopted method which uses ssDNA and ZFNs to edit human genomic DNA and founded the Sigma-Aldrich CRISPR patent estate.

Gregory received his B.S. in Chemical Engineering from the University of Texas at Austin and his Ph.D. in Chemical Engineering from the University of Oklahoma.